US approves gene therapy to treat inherited vision loss
The US Food and Drug Administration has approved a new gene therapy 'Luxturna' to treat children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna, whose safety and efficacy were established in a 41-patient trial, is the first directly administered gene therapy that targets a disease caused by mutations in a specific gene.